Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

BACKGROUND: We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific T-cell responses. METHODS: PBMCs were obtained from 10 HIV(+) individuals enrolled in trial NCT02961829. Monocytes w...

Descripción completa

Detalles Bibliográficos
Autores principales: de Almeida Baptista, Marcella Vassão, da Silva, Laís Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abrão, Cunha-Neto, Edécio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salomão, Reinaldo, da Silva Duarte, Alberto José, Janini, Luís Mário, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, Diaz, Ricardo Sobhie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753935/
https://www.ncbi.nlm.nih.gov/pubmed/35022035
http://dx.doi.org/10.1186/s12981-021-00426-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753935/
https://www.ncbi.nlm.nih.gov/pubmed/35022035
http://dx.doi.org/10.1186/s12981-021-00426-z

Ejemplares similares